Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.
We developed a rapid, specific and sensitive method based on high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) to determine icotinib concentrations in human plasma and urine. Liquid-liquid extraction (LLE) and direct dilution were firstly used to isolate icotinib from plasma and urine followed by injection of the extracts onto a C(18) column with gradient elution. Ionization of icotinib and midazolam (internal standard, IS) was performed using an electrospray ionization source in positive mode and detection was carried out in multi-reaction monitoring (MRM) mode. The lower limits of quantitation (LLoQ) of icotinib in human plasma and urine by this method were 0.1 and 1.00ng/mL, respectively. The accuracy, precision, specificity, recovery, matrix effect, linearity and several of stabilities have been validated for icotinib in human plasma and urine. In conclusion, the validation results showed that this method is robust, specific and sensitive and it can successfully fulfill the requirement of clinical pharmacokinetic study of icotinib hydrochloride in Chinese healthy subjects.
Liu
Dongyang
D
Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, 1 Shuai Fu Yuan, Dong Chen District, Beijing 100730, China.
Jiang
Ji
J
Hu
Pei
P
Tan
Fenlai
F
Wang
Yingxiang
Y
D000970:Antineoplastic Agents / Q000097:blood / Q000652:urine; D002853:Chromatography, Liquid / Q000379:methods*; D043844:Crown Ethers / Q000097:blood* / Q000652:urine*; D006801:Humans; D011799:Quinazolines / Q000097:blood* / Q000652:urine*; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*
D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib